https://www.businesswire.com/news/home/20180602005089/en/

CHICAGO--(BUSINESS WIRE)--Jun 2, 2018--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer—non-small cell local-regional/small cell/other thoracic cancers session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“We look forward to sharing insights on protein targets of multiple approved and investigational therapies to identify treatment options for patients with SCLC,” said Patrick Soon-Shiong, MD, founder of NantWorks. “Platinum doublet therapy has been a standard treatment for patients with SCLC, yet patients typically survive less than one year. Our study brings us closer to potentially identifying SCLC treatments based on individuals’ responses to targeted protein therapy.”